Alzheimer’s new treatment 2026 is no longer just a headline — it is a clinical reality changing lives for seniors diagnosed with early Alzheimer’s disease. Two groundbreaking drugs, Leqembi (lecanemab) and Donanemab (Kisunla), have received FDA approval and are now being administered in clinics across the country. If you or a loved one has been recently diagnosed with mild cognitive impairment or early Alzheimer’s, this guide explains everything you need to know right now.
What Are Leqembi and Donanemab? How Do They Work?
Both drugs belong to a class called anti-amyloid monoclonal antibodies. They target amyloid plaques — the sticky protein clumps in the brain that are a hallmark of Alzheimer’s disease. By clearing these plaques, the drugs aim to slow the progression of cognitive decline rather than simply masking symptoms.
Leqembi (lecanemab), developed by Eisai and Biogen, received full FDA approval in July 2023. It is given as an intravenous infusion every two weeks. Clinical trials showed it slowed cognitive decline by approximately 27% compared to placebo over 18 months — a meaningful effect that was statistically significant.
Donanemab (Kisunla), developed by Eli Lilly, received full FDA approval in July 2024. It is given monthly by IV infusion. The TRAILBLAZER-ALZ 2 trial showed it slowed decline by up to 35% in patients with low-to-medium tau protein levels. Notably, about 72% of participants were able to stop treatment after 12 months once their plaques were cleared — making it potentially a finite course of therapy rather than a lifelong treatment.
Who Qualifies for These Alzheimer’s Treatments in 2026?
These drugs are not for everyone with Alzheimer’s. They are specifically indicated for patients with early symptomatic Alzheimer’s disease, meaning:
- Mild cognitive impairment (MCI) due to Alzheimer’s
- Mild Alzheimer’s dementia (early stage)
- Confirmed amyloid pathology (via PET scan or cerebrospinal fluid test)
They are not appropriate for moderate or severe Alzheimer’s, as clinical evidence does not support use at those stages. Patients on blood thinners such as warfarin or apixaban face higher risks and require careful individual assessment.
| Drug | Dosing | Trial Slowing of Decline | Duration |
|---|---|---|---|
| Leqembi (lecanemab) | IV every 2 weeks | ~27% | Ongoing (chronic) |
| Donanemab (Kisunla) | IV monthly | Up to 35% | ~12 months then stop |
Does Medicare Cover Leqembi and Donanemab in 2026?
Yes — this is the critical update for 2026. Medicare began covering FDA-approved anti-amyloid Alzheimer’s therapies under Medicare Part B following a revised National Coverage Determination (NCD) in 2023. As of 2026, Medicare covers:
- The drug infusion itself (80% after the $283 Part B deductible)
- Required amyloid PET scans for confirmed diagnosis (one per patient)
- Monitoring MRIs for ARIA (brain swelling/bleeding — see below)
Coverage requires that treatment be provided in a clinical setting and that the prescribing physician participate in a CMS-approved registry to monitor outcomes. Without enrollment in the registry, Medicare will not cover the drugs. Your neurologist should handle this requirement automatically at qualified Alzheimer’s centers.
Out-of-pocket costs under Original Medicare can be significant — approximately $5,000–$20,000 per year after the 20% coinsurance — making Medigap Plan G or a Medicare Advantage plan’s drug coverage important to review. Patient assistance programs through Eisai and Eli Lilly also exist for lower-income patients.
What Is ARIA — The Key Safety Risk Every Senior Must Understand
The most important safety concern with both drugs is ARIA (Amyloid-Related Imaging Abnormalities) — brain swelling (ARIA-E) or microbleeds (ARIA-H) detected on MRI scans. ARIA is common:
- ARIA occurred in about 37% of Leqembi patients (most were asymptomatic)
- Symptomatic ARIA (causing headache, confusion, dizziness) occurred in about 3%
- Serious ARIA (requiring hospitalization) occurred in under 1%
- Donanemab had similar rates; APOE e4 gene carriers face higher ARIA risk
Because of this risk, regular MRI monitoring is mandatory — typically before treatment starts and at specific intervals during the first year. Patients with certain pre-existing small vessel disease or who are taking blood thinners require especially careful evaluation.
How to Access These Treatments: 5 Steps for Seniors in 2026
- Get a formal cognitive evaluation — Ask your primary care doctor for a referral to a neurologist or memory center specializing in Alzheimer’s. Bring a family member who can describe changes they’ve noticed over time.
- Confirm amyloid pathology — An amyloid PET scan or cerebrospinal fluid (CSF) biomarker test is required before treatment. Medicare covers one amyloid PET per patient with appropriate documentation.
- Get genotyped for APOE e4 — Many centers recommend genetic testing before starting therapy. Having one or two copies of APOE e4 significantly increases ARIA risk and changes the risk-benefit calculation.
- Verify your Medicare coverage and out-of-pocket costs — Call 1-800-MEDICARE (1-800-633-4227) or visit Medicare.gov to confirm your plan’s coverage. If costs are prohibitive, ask about manufacturer patient assistance programs.
- Find a qualified infusion center — Not all clinics offer these therapies. Use the Alzheimer’s Association’s Alzheimer’s and Dementia Caregiver Center at alz.org or call their helpline at 1-800-272-3900 to find certified treatment centers near you.
Important Perspective: What These Drugs Can and Cannot Do
I want to be honest with you about what these treatments mean. Slowing cognitive decline by 27–35% is genuinely significant — it may mean an extra 6–12 months of independence, clear communication with loved ones, and maintained dignity. For a disease that has had no disease-modifying treatment for 20 years, this represents a real breakthrough.
However, these drugs do not cure Alzheimer’s disease. They do not restore lost memory. They slow the progression. Patients will still experience cognitive decline over time. The goal is to preserve function and quality of life for as long as possible — and that goal, even if modest, matters enormously to patients and families.
Research is accelerating rapidly. Combination therapies targeting tau protein, neuroinflammation, and synaptic health are in clinical trials. The next 3–5 years may bring even more meaningful advances.
Other Alzheimer’s Management Strategies That Complement Drug Therapy
Whether or not you are a candidate for anti-amyloid therapy, these evidence-based strategies protect brain health and work alongside any treatment:
- Exercise: 150 minutes of moderate aerobic activity per week increases BDNF (brain-derived neurotrophic factor) and reduces amyloid buildup
- MIND diet: Rich in leafy greens, berries, fish, olive oil, and nuts — associated with 21% lower dementia risk in observational studies
- Sleep quality: The brain clears amyloid during deep sleep via the glymphatic system; 7–9 hours is protective
- Blood pressure control: Midlife hypertension is a major modifiable risk factor; target under 130/80
- Social engagement and cognitive stimulation: Learning new skills, social connection, and mentally challenging activities support cognitive reserve
Sources
1. FDA — Leqembi (lecanemab) Prescribing Information
2. National Institute on Aging — Alzheimer’s Disease Treatment
3. Medicare.gov — Treatments for Alzheimer’s Disease
Related Articles You May Find Helpful
- Memory Loss vs. Dementia in Seniors 2026: How to Tell the Difference
- Medicare Cancer Treatment Coverage 2026: What Seniors Must Know
- NAD+ Supplements for Seniors 2026: The Anti-Aging Molecule Explained
- Potassium for Seniors 2026: Benefits, Deficiency Signs & Best Foods
- Vertigo in Seniors 2026: Causes, Treatment & Fall Prevention Guide
